Weight loss drug study for people with endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with stage I–III endometrial cancer and had surgery with no cancer left behind
- You are about to start or have recently started chemotherapy (carboplatin and paclitaxel) with or without radiation
- You are overweight (BMI of 27 or more) with a weight-related health condition, or have obesity (BMI 30 or more), or have type 2 diabetes with a BMI of 25 or more
- You are able and willing to give yourself daily injections of the study drug, or have someone who can help you
- You have insurance that covers the drug, or can pay for it yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial is testing whether a weight-loss medication called semaglutide combined with a hormonal intrauterine device (IUD) can help treat early-stage endometrial cancer or precancerous changes, allowing patients who want to preserve fertility or avoid surgery to do so. The study also includes a structured weight loss program.
This study tests a weight-loss medication called semaglutide (Wegovy) combined with a hormonal intrauterine device (Mirena) for treating early-stage uterine cancer or precancerous changes in the uterus, while preserving fertility. The goal is to see if this combination can shrink or eliminate the abnormal cells, allowing patients to keep the option of having children.
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.